• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

North American Scientific Hosts Radiation Oncology & IMRT Technology Symposium in China; Experts From the United States and China Presented on NOMOS Products

Posted on: Wednesday, 7 June 2006, 09:01 CDT

North American Scientific, Inc. (Nasdaq:NASI), a leading manufacturer of radiation therapy products, held a symposium titled "Radiation Oncology and IMRT Technology" in Guangzhou City, China from June 2 - June 4, which featured presentations by six radiation oncology experts from the United States and China. Presenters discussed the applications of North American Scientific's NOMOS(R) products in clinical settings, specifically PEACOCK(R), an integrated IMRT planning and delivery system, CORVUS(R) treatment planning software, and BAT(R), which uses ultrasound images to confirm the location of organs and tumor sites within the patient's body.

Approximately 50 oncologists, physicists and distributors from mainland China and Hong Kong attended the symposium. Participants viewed demonstrations of the PEACOCK(R) system at Sun Yat Sen Hospital, a prestigious oncology hospital in Southern China, and learned about how the hospital uses PEACOCK(R) in its radiation oncology program. Participants also attended demonstrations of the CORVUS(R) and BAT(R) systems and learned how to operate them.

"The attendees were very impressed with NOMOS(R) products," said L. Michael Cutrer, President & Chief Executive Officer of North American Scientific. "After hearing testimony about the advantages of the NOMOS(R) system and how the system could be added to a facility's current equipment for a relatively lower cost, at a number of sites expressed interest in purchasing NOMOS(R) products. Since many facilities in China have linear accelerators in place, a NOMOS(R) upgrade makes sense fiscally, while at the same time providing high quality care."

"We are extremely pleased with the success of the China symposium and the feedback we have received," continued Mr. Cutrer. "NOMOS(R) offers a high-quality IMRT system that can be added to a facility's existing linear accelerator without the need to purchase a costly IMRT-enabled linear accelerator, which allows facilities to upgrade to the latest technology in an affordable manner. We look forward to continuing our relationships with these doctors and further expanding our business in China."

About North American Scientific

North American Scientific is a leader in radiation therapy products and services in the fight against cancer. Its innovative products provide physicians with a set of tools for the treatment of various types of cancers. They include radioisotope-based brachytherapy seeds, used primarily in the treatment of prostate cancer, marketed under the trade name Prospera(R); Intensity Modulated Radiation Therapy (IMRT); and Image Guided Radiation Therapy (IGRT). IMRT allows an escalated radiation dose to be delivered to a tumor while limiting exposure and damage to nearby healthy tissue. The Company's principal IMRT products are marketed under the trade names PEACOCK(R) and CORVUS. The Company's IGRT products, BAT(R), BATCAM(TM) and nTRAK(TM) provide fast and accurate targeting and localization of a treatment volume on a daily basis. Over 500 hospitals and research sites worldwide are equipped with the Company's clinically proven PEACOCK, CORVUS (our proprietary treatment planning software), BAT, BATCAM, and ancillary treatment solutions. Please visit www.nasmedical.com for more information.

Statements included in this release that are not historical facts may be considered forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company including, but not limited to, the impact of competitive products and pricing, technological changes, changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements, the ability of the Company to successfully directly market and sell its products, uncertainties relating to patent protection and regulatory approval, the stable supply of appropriate isotopes, research and development estimates, market opportunities, risks associated with strategic opportunities or acquisitions the Company may pursue and the risk factors included in the Company's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this news release speak only as of the date of this release, and the Company undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future results or otherwise.

Source: Business Wire

More News in this Category